This expert brief reviews why adults aged 65 and older face the highest risk of severe influenza outcomes and highlights the importance of enhanced vaccination in this population. It explains how immunosenescence and multiple comorbidities increase vulnerability, and summarizes the evidence showing that high-dose influenza vaccines offer the strongest protection against hospitalization and related complications. The session also outlines current NACI recommendations and provides practical strategies to boost vaccine uptake, such as using EMR alerts, offering vaccination at every clinical touchpoint, and using confident, presumptive language to guide patient decisions.
This program has received an unrestricted educational grant or in-kind support from Sanofi Canada.